agilon health, inc. (AGL) Stock Analysis and Metrics

Sector: Healthcare Industry: Medical Care Facilities CIK: 0001831097

Market Cap 1.53 Bn

P/E 46.84

P/S 0.26

Div. Yield 0.00

ROIC (Qtr) -0.02

Total Debt (Qtr) 30.03 Mn

Revenue Growth (1y) (Qtr) -7.33

Add ratio to table...

About

agilon health, inc. empowers primary care physicians to act as agents of change in their communities by providing a platform that supports a Medicare centered globally capitated model of care. The company forms risk bearing entities that contract with health plan payors to receive monthly payments for managing the total health care needs of attributed patients. Through long term partnerships with existing physician groups agilon health, inc. supplies technology people processes and capital to help those groups transition to a total care approach....

agilon health, inc. empowers primary care physicians to act as agents of change in their communities by providing a platform that supports a Medicare centered globally capitated model of care. The company forms risk bearing entities that contract with health plan payors to receive monthly payments for managing the total health care needs of attributed patients. Through long term partnerships with existing physician groups agilon health, inc. supplies technology people processes and capital to help those groups transition to a total care approach. As of December 31, 2025 the company had partnerships with 28 anchor physician groups operating in 30 geographies and served approximately 511,000 Medicare Advantage members and 114,000 Medicare fee for service beneficiaries.

Revenue is derived from per member per month capitated fees that health plan payors pay to the risk bearing entities for each attributed Medicare beneficiary. These fees are based on a percentage of the premium payments that payors receive from CMS for the members and are typically renewed on an annual or multi year basis. When the cost of care for the attributed population falls below the received premiums the company shares the resulting savings with its physician partners and may also receive quality bonus payments from payors. Additional revenue can come from incentive payments tied to performance metrics in the CMS ACO models where the company participates through its equity method investments.

agilon health, inc. operates in the competitive value based care landscape where it faces rivals such as other dedicated value based providers large health plans with internal managed care programs and local hospital systems. The company differentiates itself through a proprietary platform that integrates data analytics care coordination tools and financial management resources. Its long term partnership model typically spanning twenty years creates stable recurring revenue streams and aligns incentives between the company and its physician partners. Furthermore the collaborative network of physicians encourages sharing of best practices and continuous improvement of the care delivery model.

The company serves health plan payors that include national insurers as well as regional and local health insurance companies. It works with 28 anchor physician groups that act as the primary care providers for the attributed patient populations. The ultimate recipients of care are Medicare beneficiaries consisting of Medicare Advantage enrollees and fee for service individuals across the United States.

Investment thesis

Bull case

Agilon Health’s core proposition—enabling physician groups and health systems to transition to a value‑based Total Care model for seniors—is aligned with a clear structural shift in U.S. healthcare toward capitation and population health management. The company’s platform, combining technology, people, capital, and a peer network of roughly 2,200 primary‑care physicians, allows physician partners to maintain independence while delivering coordinated care, a compelling differentiator in a market saturated with fee‑for‑service incumbents. Although the most recent quarter reflected negative margins, the incremental 28 % of members not previously captured in the second‑quarter results signals the company’s ability to incorporate new payors into its data pipeline, which should strengthen risk‑adjusted revenue accuracy and unlock higher per‑member revenues in 2026. Moreover, the disclosed expectation of a $30 million operating expense reduction in 2026, driven by streamlined geography entry and platform support costs, demonstrates a tangible path to improved cash flow once the platform’s cost‑basis is diluted across a larger member base. If the organization can sustain its physician partnership model and continue to onboard new Medicare Advantage and ACO REACH members, the long‑term economics of the Total Care model could translate into a positive medical margin and eventual profitability, positioning Agilon as a pioneer in an industry that is steadily moving away from volume‑based reimbursement.
The company’s recent financial disclosure highlighted a strategic focus on data visibility and financial discipline in payer contracting, both of which are critical in a healthcare environment that increasingly rewards outcome performance and cost containment. By tightening risk‑adjustment calculations and negotiating more favorable rates, Agilon has already begun to offset the impact of market exits, and its guidance projects a shift from a negative to a modest positive adjusted EBITDA in 2025, reflecting a potential turning point once the initial investment phase subsides. Importantly, the inclusion of unconsolidated ACO entities that contributed $18 million to adjusted EBITDA in the third quarter suggests that Agilon’s value‑based contracts are generating tangible revenue streams even outside its consolidated financials, indicating a broader opportunity for scaling these relationships. The company’s platform, built for rapid deployment across diverse geographic markets, offers the scalability needed to capture a growing share of the Medicare Advantage and ACO segments, which are projected to grow at double‑digit rates over the next decade. Together, these catalysts imply that Agilon could capitalize on a national trend toward value‑based care, generating sustainable growth once the current capital expenditures are amortized.
Agilon’s partnership model creates a virtuous cycle: physician partners bring patients, and the platform’s analytics provide them with better care coordination, potentially reducing acute care utilization and associated costs. This model directly addresses the high‑cost segment of the senior population, which is expected to expand as the U.S. baby‑boomer cohort ages, thereby creating a sizable addressable market. The company’s ability to attract a peer network of 2,200 PCPs indicates a strong operational foundation and a community‑driven incentive structure that aligns physician and patient interests—an element that could accelerate adoption rates relative to competitors. Even though the company’s current loss profile and cash burn are material, its balance sheet remains relatively healthy, with $311 million in cash and marketable securities and only $35 million in debt, providing runway to weather short‑term volatility and invest in platform enhancements. If Agilon can maintain physician engagement, secure favorable payer contracts, and optimize its cost structure, it stands to capture a significant portion of the emerging value‑based care market, potentially justifying a valuation premium over peers that remain entrenched in fee‑for‑service models.
The Q3 2025 results disclosed a 6 % decline in total members and a negative medical margin, but the company reported a 2 % improvement in net loss and a 5 % decrease in adjusted EBITDA loss compared to the same period a year earlier, illustrating incremental operational efficiencies. The leadership transition that saw the CEO depart and the company suspend its 2025 guidance may have temporarily unsettled investor sentiment, yet it also signals an internal recalibration toward a more disciplined execution plan. The company's stated focus on reducing geography entry costs and improving platform support suggests that the organization is actively addressing the high upfront costs associated with expansion—a critical hurdle for any health‑tech platform seeking scale. Given the projected $30 million operating expense savings in 2026, Agilon has the potential to turn its cash‑burn trajectory into a path to profitability, provided it can maintain or grow its member base and secure sustained payer contracts. These incremental gains, if sustained, could be a hidden catalyst for a positive earnings trajectory that is currently underappreciated by the market.

Agilon Health’s core proposition—enabling physician groups and health systems to transition to a value‑based Total Care model for seniors—is aligned with a clear structural shift in U.S. healthcare toward capitation and population health management. The company’s platform, combining technology, people, capital, and a peer network of roughly 2,200 primary‑care physicians, allows physician partners to maintain independence while delivering coordinated care, a compelling differentiator in a market saturated with fee‑for‑service incumbents. Although the most recent quarter reflected negative margins, the incremental 28 % of members not previously captured in the second‑quarter results signals the company’s ability to incorporate new payors into its data pipeline, which should strengthen risk‑adjusted revenue accuracy and unlock higher per‑member revenues in 2026. Moreover, the disclosed expectation of a $30 million operating expense reduction in 2026, driven by streamlined geography entry and platform support costs, demonstrates a tangible path to improved cash flow once the platform’s cost‑basis is diluted across a larger member base. If the organization can sustain its physician partnership model and continue to onboard new Medicare Advantage and ACO REACH members, the long‑term economics of the Total Care model could translate into a positive medical margin and eventual profitability, positioning Agilon as a pioneer in an industry that is steadily moving away from volume‑based reimbursement.
The company’s recent financial disclosure highlighted a strategic focus on data visibility and financial discipline in payer contracting, both of which are critical in a healthcare environment that increasingly rewards outcome performance and cost containment. By tightening risk‑adjustment calculations and negotiating more favorable rates, Agilon has already begun to offset the impact of market exits, and its guidance projects a shift from a negative to a modest positive adjusted EBITDA in 2025, reflecting a potential turning point once the initial investment phase subsides. Importantly, the inclusion of unconsolidated ACO entities that contributed $18 million to adjusted EBITDA in the third quarter suggests that Agilon’s value‑based contracts are generating tangible revenue streams even outside its consolidated financials, indicating a broader opportunity for scaling these relationships. The company’s platform, built for rapid deployment across diverse geographic markets, offers the scalability needed to capture a growing share of the Medicare Advantage and ACO segments, which are projected to grow at double‑digit rates over the next decade. Together, these catalysts imply that Agilon could capitalize on a national trend toward value‑based care, generating sustainable growth once the current capital expenditures are amortized.
Agilon’s partnership model creates a virtuous cycle: physician partners bring patients, and the platform’s analytics provide them with better care coordination, potentially reducing acute care utilization and associated costs. This model directly addresses the high‑cost segment of the senior population, which is expected to expand as the U.S. baby‑boomer cohort ages, thereby creating a sizable addressable market. The company’s ability to attract a peer network of 2,200 PCPs indicates a strong operational foundation and a community‑driven incentive structure that aligns physician and patient interests—an element that could accelerate adoption rates relative to competitors. Even though the company’s current loss profile and cash burn are material, its balance sheet remains relatively healthy, with $311 million in cash and marketable securities and only $35 million in debt, providing runway to weather short‑term volatility and invest in platform enhancements. If Agilon can maintain physician engagement, secure favorable payer contracts, and optimize its cost structure, it stands to capture a significant portion of the emerging value‑based care market, potentially justifying a valuation premium over peers that remain entrenched in fee‑for‑service models.
The Q3 2025 results disclosed a 6 % decline in total members and a negative medical margin, but the company reported a 2 % improvement in net loss and a 5 % decrease in adjusted EBITDA loss compared to the same period a year earlier, illustrating incremental operational efficiencies. The leadership transition that saw the CEO depart and the company suspend its 2025 guidance may have temporarily unsettled investor sentiment, yet it also signals an internal recalibration toward a more disciplined execution plan. The company's stated focus on reducing geography entry costs and improving platform support suggests that the organization is actively addressing the high upfront costs associated with expansion—a critical hurdle for any health‑tech platform seeking scale. Given the projected $30 million operating expense savings in 2026, Agilon has the potential to turn its cash‑burn trajectory into a path to profitability, provided it can maintain or grow its member base and secure sustained payer contracts. These incremental gains, if sustained, could be a hidden catalyst for a positive earnings trajectory that is currently underappreciated by the market.

Bear case

The most recent quarterly report underscored a persistent negative medical margin of $57 million and a net loss of $110 million, while membership declined by 6 % year‑over‑year, raising immediate concerns about Agilon’s ability to achieve sustainable cash flow. A key structural risk is the company’s heavy reliance on a limited number of Medicare Advantage and ACO payors; any unfavorable contract renegotiation or loss of a major payer could disproportionately impact revenue, especially given the current low risk‑adjustment performance. Additionally, the company’s guidance for the full year 2025 includes a $150 million hit from lower‑than‑expected risk‑adjusted revenue and a $60 million impact from exited markets, implying that the business is still grappling with headwinds that could erode the already narrow operating margins. The sudden CEO departure and the subsequent suspension of 2025 guidance reflect governance volatility, while the multiple class‑action lawsuits alleging misleading statements and reckless guidance issuance cast doubt on the credibility of management’s disclosures and forecast assumptions. Combined, these factors signal a high degree of uncertainty that could lead to further revenue erosion and continued losses if the company fails to secure stable payer contracts or control operating costs.
Agilon’s financial statements reveal that a significant portion of its operating expenses—approximately $1.9 million in the third quarter alone—was attributed to physician compensation and care‑management expenses that may be dilutive until the platform’s revenue base matures. The company's $172 million of cash associated with unconsolidated ACO entities indicates that a substantial portion of its earnings is tied to non‑consolidated operations, which raises questions about the transparency and control over these cash flows. The company’s reliance on equity‑method investments for a portion of its revenue further complicates earnings attribution, as fluctuations in partner performance directly influence Agilon’s profitability. Furthermore, the ongoing litigation and investigations by multiple law firms highlight potential material misstatements and a pattern of insufficient disclosure, which could trigger regulatory penalties, investor lawsuits, and reputational damage that may depress share price and hamper capital raising. In the event that the company is unable to resolve these governance and disclosure issues, it could face increased scrutiny from regulators and shareholders, potentially leading to higher cost of capital and stricter oversight.
The operational model of transitioning physician groups to a Total Care model is inherently risky, requiring high levels of physician engagement, technology adoption, and cultural change. The company’s platform support costs, which were $38.7 million in the third quarter, represent a significant overhead that is unlikely to recoup until a large and mature membership base is achieved. The company’s member growth trajectory has stalled, with Medicare Advantage members down 4 % and ACO members down 13 % year‑over‑year, suggesting that expansion into new markets is slower than anticipated. The guidance indicates that the company will incur geography entry costs of $32 million in 2025, a substantial capital outlay that may not yield immediate returns and could exacerbate liquidity pressures if revenue growth does not accelerate. Given the current negative gross profit and the need for continued investment in technology and personnel, Agilon faces a classic startup cash‑burn problem that could culminate in a funding shortfall or an unfavorable equity dilution event.
Agilon’s dependence on a limited number of high‑margin Medicare Advantage contracts exposes it to payer‑side risk, especially in a highly regulated environment where reimbursement rates and contract terms are subject to rapid change. The company’s disclosures suggest that the risk‑adjustment revenue contributed a $73 million shortfall in Q3 2025, largely due to a single payer’s data integration challenges; this indicates a susceptibility to data and actuarial miscalculations that could recur. Additionally, the company’s strategy of scaling through physician partnerships may face resistance from incumbent health systems that prefer in‑house or larger platform solutions, limiting Agilon’s ability to penetrate new markets. The lawsuits alleging misstatements about guidance and risk mitigation suggest that management may have over‑optimistically portrayed the company’s financial prospects, potentially misleading investors and creating a market valuation that is not aligned with the underlying business fundamentals. In a scenario where payer contracts become less favorable or physician engagement wanes, Agilon could experience rapid revenue erosion and be forced to further cut costs, possibly leading to insolvency or a forced sale of assets.

The most recent quarterly report underscored a persistent negative medical margin of $57 million and a net loss of $110 million, while membership declined by 6 % year‑over‑year, raising immediate concerns about Agilon’s ability to achieve sustainable cash flow. A key structural risk is the company’s heavy reliance on a limited number of Medicare Advantage and ACO payors; any unfavorable contract renegotiation or loss of a major payer could disproportionately impact revenue, especially given the current low risk‑adjustment performance. Additionally, the company’s guidance for the full year 2025 includes a $150 million hit from lower‑than‑expected risk‑adjusted revenue and a $60 million impact from exited markets, implying that the business is still grappling with headwinds that could erode the already narrow operating margins. The sudden CEO departure and the subsequent suspension of 2025 guidance reflect governance volatility, while the multiple class‑action lawsuits alleging misleading statements and reckless guidance issuance cast doubt on the credibility of management’s disclosures and forecast assumptions. Combined, these factors signal a high degree of uncertainty that could lead to further revenue erosion and continued losses if the company fails to secure stable payer contracts or control operating costs.
Agilon’s financial statements reveal that a significant portion of its operating expenses—approximately $1.9 million in the third quarter alone—was attributed to physician compensation and care‑management expenses that may be dilutive until the platform’s revenue base matures. The company's $172 million of cash associated with unconsolidated ACO entities indicates that a substantial portion of its earnings is tied to non‑consolidated operations, which raises questions about the transparency and control over these cash flows. The company’s reliance on equity‑method investments for a portion of its revenue further complicates earnings attribution, as fluctuations in partner performance directly influence Agilon’s profitability. Furthermore, the ongoing litigation and investigations by multiple law firms highlight potential material misstatements and a pattern of insufficient disclosure, which could trigger regulatory penalties, investor lawsuits, and reputational damage that may depress share price and hamper capital raising. In the event that the company is unable to resolve these governance and disclosure issues, it could face increased scrutiny from regulators and shareholders, potentially leading to higher cost of capital and stricter oversight.
The operational model of transitioning physician groups to a Total Care model is inherently risky, requiring high levels of physician engagement, technology adoption, and cultural change. The company’s platform support costs, which were $38.7 million in the third quarter, represent a significant overhead that is unlikely to recoup until a large and mature membership base is achieved. The company’s member growth trajectory has stalled, with Medicare Advantage members down 4 % and ACO members down 13 % year‑over‑year, suggesting that expansion into new markets is slower than anticipated. The guidance indicates that the company will incur geography entry costs of $32 million in 2025, a substantial capital outlay that may not yield immediate returns and could exacerbate liquidity pressures if revenue growth does not accelerate. Given the current negative gross profit and the need for continued investment in technology and personnel, Agilon faces a classic startup cash‑burn problem that could culminate in a funding shortfall or an unfavorable equity dilution event.
Agilon’s dependence on a limited number of high‑margin Medicare Advantage contracts exposes it to payer‑side risk, especially in a highly regulated environment where reimbursement rates and contract terms are subject to rapid change. The company’s disclosures suggest that the risk‑adjustment revenue contributed a $73 million shortfall in Q3 2025, largely due to a single payer’s data integration challenges; this indicates a susceptibility to data and actuarial miscalculations that could recur. Additionally, the company’s strategy of scaling through physician partnerships may face resistance from incumbent health systems that prefer in‑house or larger platform solutions, limiting Agilon’s ability to penetrate new markets. The lawsuits alleging misstatements about guidance and risk mitigation suggest that management may have over‑optimistically portrayed the company’s financial prospects, potentially misleading investors and creating a market valuation that is not aligned with the underlying business fundamentals. In a scenario where payer contracts become less favorable or physician engagement wanes, Agilon could experience rapid revenue erosion and be forced to further cut costs, possibly leading to insolvency or a forced sale of assets.

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	84.64 Bn	12.86	1.11	48.02 Bn
2	THC	Tenet Healthcare Corp	15.22 Bn	9.05	0.71	13.21 Bn
3	DVA	Davita Inc.	13.10 Bn	18.35	0.94	10.63 Bn
4	EHC	Encompass Health Corp	10.50 Bn	17.41	1.73	2.57 Bn
5	ENSG	Ensign Group, Inc	9.69 Bn	26.48	1.84	0.14 Bn
6	UHS	Universal Health Services Inc	8.92 Bn	6.02	0.50	4.71 Bn
7	FMS	Fresenius Medical Care AG	7.31 Bn	-0.62	0.00	8.48 Bn
8	CHE	Chemed Corp	5.83 Bn	23.22	2.30	0.09 Bn

Research Tools

Developers

agilon health, inc. (NYSE: AGL)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Research Tools

Developers

agilon health, inc. (NYSE: AGL)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password